Our resultshelp explain why pathological mutations in CB1 (e.g., chronicpain) do not always provide insight into the side effects of CB1 suppression (e.g., clinical depression), and thus urge morepreclinical studies for any drugs that suppress CB1. The gene discussed is CNR1; the disease is depressive disorder.